Cancer development is highly associated to the physiological state of the tumor
microenvironment (TME). Despite the existing heterogeneity of tumors from the same or from …

Cancer immunotherapy is revolutionizing oncology. However, dose-limiting toxicities and
low patient response rates remain major challenges in the clinic. Cancer nanomedicine in …

The study of nanostructured drug delivery systems allows the development of novel
platforms for the efficient transport and controlled release of drug molecules in the harsh …

Recent findings suggest that the cellular and extracellular materials surrounding the
cancerous cells from an atypical tumor microenvironment (TM) play a pivotal role in the …

Cancer immunotherapy and vaccine development have significantly improved the fight
against cancers. Despite these advancements, challenges remain, particularly in the clinical …

Nanotechnology is reshaping health care strategies and is expected to exert a tremendous
impact in the coming years offering better healthcare facilities. It has led to not only …

The development of therapeutic resistance to targeted anticancer therapies remains a
significant clinical problem, with intratumoral heterogeneity playing a key role. In this context …

Tailoring personalized cancer nanomedicines demands detailed understanding of the tumor
microenvironment. In recent years, smart upconversion nanoparticles with the ability to …

Successful delivery of drugs and nanomedicine to tumors requires a functional vascular
network, extravasation across the capillary wall, penetration through the extracellular matrix …

RNA interference (RNAi) uses small interfering RNAs (siRNAs) to mediate gene-silencing in
cells and represents an emerging strategy for cancer therapy. Successful RNAi-mediated …